Among people with fatty liver disease, those with thyroid-stimulating hormone levels in the upper half of the normal range (2.5–4.5 mIU/L) are more likely to have advanced liver scarring than those with lower normal levels, even after accounting for obesity and diabetes.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis would determine whether the association between TSH 2.5–4.5 mIU/L and NFS > 0.676 is consistent across diverse populations and ethnicities.
Systematic review and meta-analysis of prospective cohort studies reporting odds ratios for NFS > 0.676 in MAFLD patients with TSH 2.5–4.5 mIU/L versus TSH < 2.5 mIU/L, adjusting for BMI, diabetes, and hypertension.
An RCT would test whether lowering TSH from 2.5–4.5 to <2.5 mIU/L reduces NFS progression in MAFLD patients, proving modifiability of risk.
Double-blind RCT of 400 MAFLD patients with TSH 2.5–4.5 mIU/L and NFS 0.3–0.676, randomized to levothyroxine (target TSH 1.5–2.0) vs. placebo for 3 years, with NFS recalculated annually as primary outcome.
A prospective cohort would determine whether TSH levels in the 2.5–4.5 mIU/L range predict future NFS increase over time, confirming temporal sequence.
Prospective cohort of 2,000 MAFLD patients with baseline TSH stratified into <2.5, 2.5–4.5, >4.5 mIU/L, followed for 5 years with annual NFS calculation, adjusting for metabolic confounders.
A case-control study would compare TSH levels between MAFLD patients with NFS > 0.676 and those with NFS < 0.676, confirming the association in a matched design.
Case-control study of 500 MAFLD patients: 250 with NFS > 0.676 and 250 with NFS < 0.676, matched for age, sex, BMI, and diabetes, measuring TSH at time of fibrosis assessment.
A cross-sectional study can only show whether TSH levels differ between those with NFS > 0.676 and those without at a single time point.
Cross-sectional analysis of 10,000 MAFLD patients with TSH and NFS measured simultaneously, comparing mean TSH between NFS > 0.676 and NFS ≤ 0.676 groups.